Psychedelics for Anxiety Disorders – From MDMA to ACT

Can psychedelics transform the treatment of anxiety disorders? What can we learn from MDMA-assisted therapy for Social Anxiety Disorder – and how might Acceptance and Commitment Therapy (ACT) strengthen psychedelic-assisted treatment?

In this in-depth conversation, clinical psychologist Filip Bromberg speaks with Jason Luoma, PhD, about the evolving role of psychedelics in the treatment of anxiety disorders.

Jason Luoma is a clinical psychologist, researcher, and internationally recognized expert in ACT. He is co-founder of Portland Psychotherapy Clinic, Research, & Training Center and has led a pioneering clinical trial investigating MDMA-assisted therapy for Social Anxiety Disorder.

In this webinar, we explore:

• Findings and clinical implications from MDMA-assisted therapy for Social Anxiety Disorder
• The broader potential of psychedelics in treating anxiety disorders
• Psychological avoidance and experiential avoidance in anxiety
• How Acceptance and Commitment Therapy (ACT) complements psychedelic-assisted therapy
• Clinical integration: preparation, dosing sessions, and integration work
• Ethical considerations and responsible implementation in clinical practice

The webinar is presented by Borealis Psychedelic Science Summit in collaboration with Lavin.